Evidence map›Paper›PMID 25148254›Full record

ArticlePloS one2014

Chronic HCV infection affects the NK cell phenotype in the blood more than in the liver.

Cormac Cosgrove, Christoph T Berger, Daniela C Kroy, Patrick C Cheney, Musie Ghebremichael, Jasneet Aneja, Michelle Tomlinson, Arthur Y Kim, Georg M Lauer, Galit Alter

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. NK-cell receptor modulation in viral infections.Clinical and experimental immunology · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. ADCC-Mediated CD56Pathogens & immunity · 2018
    Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Cormac CosgroveRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Christoph T BergerRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Daniela C KroyMassachusetts General Hospital, Boston, Massachusetts, United States of America; Medical Department 3, RWTH Aachen University Hospital, Aachen, Germany.
Patrick C CheneyRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Musie GhebremichaelRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Jasneet AnejaMassachusetts General Hospital, Boston, Massachusetts, United States of America.
Michelle TomlinsonMassachusetts General Hospital, Boston, Massachusetts, United States of America.
Arthur Y KimMassachusetts General Hospital, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America.
Georg M LauerMassachusetts General Hospital, Boston, Massachusetts, United States of America; Harvard Medical School, Boston, Massachusetts, United States of America.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Ragon Institute of MGH, MIT and Harvard · USMassachusetts General Hospital · USHarvard University · USUniversitätsklinikum Aachen · DE

Funding

The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2005 to 2014
$8.5M
NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI08230
6 · The paper itself

Abstract

Although epidemiological and functional studies have implicated NK cells in protection and early clearance of HCV, the mechanism by which they may contribute to viral control is poorly understood, particularly at the site of infection, the liver. We hypothesized that a unique immunophenotypic/functional NK cell signature exists in the liver that may provide insights into the contribution of NK cells to viral control. Intrahepatic and blood NK cells were profiled from chronically infected HCV-positive and HCV-negative individuals. Baseline expression of activating and inhibitory receptors was assessed, as well as functional responses following stimulation through classic NK cell pathways. Independent of HCV infection, the liver was enriched for the immunoregulatory CD56(bright) NK cell population, which produced less IFNγ and CD107a but comparable levels of MIP1β, and was immunophenotypically distinct from their blood counterparts. This profile was mostly unaltered in chronic HCV infection, though different expression levels of NKp46 and NKG2D were associated with different grades of fibrosis. In contrast to the liver, chronic HCV infection associated with an enrichment of CD161(low)perforin(high) NK cells in the blood correlated with increased AST and 2B4 expression. However, the association of relatively discrete changes in the NK cell phenotype in the liver with the fibrosis stage nevertheless suggests an important role for the NK response. Overall these data suggest that tissue localization has a more pervasive effect on NK cells than the presence of chronic viral infection, during which these cells might be mostly attuned to limiting immunopathology. It will be important to characterize NK cells during early HCV infection, when they should have a critical role in limiting infection.

Indexed as

AgedCD56 AntigenFemaleHepatitis C, ChronicHumansImmunophenotypingKiller Cells, NaturalLiverLiver CirrhosisMaleMiddle AgedNatural Cytotoxicity Triggering Receptor 1NK Cell Lectin-Like Receptor Subfamily BNK Cell Lectin-Like Receptor Subfamily KPerforinPhenotypeCD56 AntigenKLRB1 protein, humanKLRK1 protein, humanNatural Cytotoxicity Triggering Receptor 1NCAM1 protein, humanNCR1 protein, humanNK Cell Lectin-Like Receptor Subfamily BNK Cell Lectin-Like Receptor Subfamily KPerforin

Identifiers

PMID25148254
PMCPMC4141847
OpenAlexW2114607732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.